Search
Eravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalIt was first approved by the FDA on August 27, 2018 [L4540]. … Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive
Insulin degludec
go.drugbank.com/drugs/DB09564ApprovedInvestigationalInsulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. … [A18561,A18562,A18563,A18564,A174934] Marketed as the brand name product Tresiba, insulin degludec has a duration of action up to 42 hours allowing for once-daily dosing, typically at bedtime.
Mixtures: Ryzodeg® FlexTouch® 100 U/ml Solution for Injection, RYZODEG PENFİLL 100 U/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KARTUŞ, 5 ADETProducts: TRESIBA® 100 U/ML, Tresiba® FlexTouch® 100 U/ml Solution for InjectionIoxaglic acid
go.drugbank.com/drugs/DB09313ApprovedWithdrawnIoxaglic acid has a low osmolarity and is associated with fewer side effects compared to older contrast agents [L1883].
Brotizolam
go.drugbank.com/drugs/DB09017ApprovedWithdrawnBrotizolam is not approved for sale in the UK, United States or Canada but is sold in the Netherlands, Germany, Spain, Belgium, Austria, Portugal, Israel, Italy and Japan.
Clotiazepam
go.drugbank.com/drugs/DB01559ApprovedIllicitClotiazepam is a thienodiazepine, not approved for sale in the U.S. or Canada, but has been approved in the U.K. It is a schedule IV drug in Canada.
Elexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigational[A187361] The triple combination product Trikafta<sup>TM</sup>, manufactured by Vertex Pharmaceuticals, is the first product approved for the treatment of CF in individuals who are either homo- _or_ heterozygous
Ivacaftor
go.drugbank.com/drugs/DB08820ApprovedInvestigationalIt is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012[L768], and by Health Canada in late 2012. … [L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein
Isavuconazonium
go.drugbank.com/drugs/DB06636ApprovedInvestigational, marketed by Astellas under the brand Cresemba. … Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis
Pegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000] Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat susceptible to hemolysis caused by C3b opsonization. … [L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354]
Calcium carbimide
go.drugbank.com/drugs/DB09116ApprovedWithdrawnIts effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of alcohol by preventing the breakdown of the metabolic product acetaldehyde. … Calcium carbimide was conceived as an alternative for the treatment of alcoholism with a reduced side effect profile either when it is consumed accompanied by alcohol or without it.